EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging Biologic Therapies for the Treatment of Atopic Dermatitis

José Miguel Alvarenga, Thomas Bieber, Tiago Torres

Drugs · 2024

DOI: 10.1007/s40265-024-02095-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von José Miguel Alvarenga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Cytokines. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universidade do Porto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a prevalent inflammatory skin disease having a significant impact on patients' quality of life. Conventional treatments, including topical therapies and systemic immunosuppressants, often have limited efficacy and long-term safety concerns. Emerging biologic therapies target specific immune pathways implicated in AD pathogenesis, offering new therapeutic options in a disease known for its complex immune pathomechanisms. This review focuses on novel biologics under investigation, particularly those targeting specific immune pathways such as interleukin-4 (IL-4), IL-13, IL-22, IL-31, thymic stromal lymphopoietin (TSLP), and OX40-OX40L axis. Interleukin-4 and IL-13 inhibitors aim to reduce Th2-driven inflammation, while IL-22 inhibitors focus on restoring skin barrier function. Interleukin-31 inhibitors help alleviate pruritus, a major symptom in AD. OX40-OX40L pathway inhibitors can selectively suppress the activity of pathogenic T cells, without inducing significant immunosuppression. Bispecific antibodies targeting both IL-4 and IL-31 pathways are emerging as potential dual-action treatment for AD. Thymic stromal lymphopoietin inhibitors offer a novel strategy to control inflammation. While many of these therapies offer promising safety and efficacy profiles, long-term studies and real-world data are essential to confirm their lasting impact. This review highlights the potential of these emerging systemic therapies to continue transforming AD management and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicCytokinesHumansBiological TherapyInterleukinsInterleukin-4Biological ProductsInterleukin-13Thymic Stromal LymphopoietinAntibodies, Bispecific

Substanzen

CytokinesInterleukinsInterleukin-4IL31 protein, humanBiological ProductsInterleukin-13Thymic Stromal LymphopoietinAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal.
  • Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
  • University of Bonn, Bonn, Germany.
  • Christine Kühne-Center for Allergy Research and Education, Medicine Campus Davos, Davos, Switzerland.
  • Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal. torres.tiago@outlook.com.
  • Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal. torres.tiago@outlook.com.

Förderung

  • Universidade do Porto

Zitieren

APA

Alvarenga, J. M., Bieber, T., & Torres, T. (2024). Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. https://doi.org/10.1007/s40265-024-02095-4

Vancouver

Alvarenga JM, Bieber T, Torres T. Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. 2024. doi:10.1007/s40265-024-02095-4

BibTeX
@article{Alvarenga2024,
  author = {Alvarenga, José Miguel and Bieber, Thomas and Torres, Tiago},
  title = {Emerging Biologic Therapies for the Treatment of Atopic Dermatitis},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-024-02095-4}
}
Kostenlos starten →